Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

famitinib

An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Famitinib binds to and inhibits several RTKs, dysregulated in a variety of tumors, including stem cell factor receptor (c-Kit; SCFR), vascular endothelial growth factor receptor (VEGFR) 2 and 3, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinases Flt1 and Flt3. Inhibition of these RTKs may result in an inhibition of tumor growth and angiogenesis, and eventually tumor regression in tumor cells overexpressing these RTKs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:SHR-1020
SHR1020
Chemical structure:4H-pyrrolo(3,2-c)pyridin-4-one, 5-(2-(diethylamino)ethyl)-2-((5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-1,5,6,7-tetrahydro-3-methyl-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search